Illumina (ILMN) and The Competition Financial Contrast

Illumina (NASDAQ:ILMN – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Illumina to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, profitability, risk and institutional ownership.

Institutional and Insider Ownership

89.4% of Illumina shares are held by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 2.9% of Illumina shares are held by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Illumina and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina 3 7 10 0 2.35
Illumina Competitors 957 3197 5533 179 2.50

Illumina currently has a consensus target price of $243.72, suggesting a potential upside of 23.09%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.61%. Given Illumina’s higher probable upside, research analysts clearly believe Illumina is more favorable than its peers.

Profitability

This table compares Illumina and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Illumina 19.72% 28.38% 12.11%
Illumina Competitors -487.63% 40.45% -13.30%

Earnings and Valuation

This table compares Illumina and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Illumina $4.34 billion $850.00 million 34.08
Illumina Competitors $2.26 billion $55.88 billion -7.66

Illumina has higher revenue, but lower earnings than its peers. Illumina is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Illumina has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Illumina’s peers have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.

Summary

Illumina beats its peers on 7 of the 13 factors compared.

Illumina Company Profile

(Get Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.